Jupiter Topco LLC Buys Shares of 39,335 Syndax Pharmaceuticals, Inc. $SNDX

Jupiter Topco LLC purchased a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 39,335 shares of the company’s stock, valued at approximately $860,000.

Other institutional investors have also recently made changes to their positions in the company. Allworth Financial LP acquired a new position in Syndax Pharmaceuticals in the second quarter valued at approximately $26,000. Smartleaf Asset Management LLC raised its position in Syndax Pharmaceuticals by 2,698.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company’s stock valued at $55,000 after purchasing an additional 2,564 shares during the period. Larson Financial Group LLC raised its position in Syndax Pharmaceuticals by 192.2% in the third quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock valued at $45,000 after purchasing an additional 1,922 shares during the period. Quantbot Technologies LP purchased a new stake in Syndax Pharmaceuticals in the third quarter valued at $53,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Syndax Pharmaceuticals in the 2nd quarter valued at $66,000.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. HC Wainwright cut their price objective on Syndax Pharmaceuticals from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Wednesday, August 5th. UBS Group reduced their price target on shares of Syndax Pharmaceuticals from $37.00 to $33.00 and set a “buy” rating on the stock in a research note on Friday, August 21st. JPMorgan Chase & Co. decreased their price objective on shares of Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 21st. Finally, Bank of America restated a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, August 5th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.30.

Syndax Pharmaceuticals Trading Down 0.6%

NASDAQ SNDX opened at $20.56 on Friday. The firm’s fifty day moving average price is $20.96 and its 200 day moving average price is $21.25. Syndax Pharmaceuticals, Inc. has a 12 month low of $12.99 and a 12 month high of $25.59. The company has a debt-to-equity ratio of 38.95, a current ratio of 6.77 and a quick ratio of 6.44. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -8.19 and a beta of 0.37.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.10). The company had revenue of $72.79 million during the quarter, compared to analysts’ expectations of $79.36 million. Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. Syndax Pharmaceuticals’s revenue was up 91.8% on a year-over-year basis. During the same period last year, the firm earned ($0.83) earnings per share. On average, sell-side analysts expect that Syndax Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 32,375 shares of the company’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $24.24, for a total transaction of $784,770.00. Following the transaction, the chief executive officer directly owned 484,843 shares in the company, valued at approximately $11,752,594.32. This represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CMO Nicholas Botwood sold 31,235 shares of the firm’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $18.14, for a total transaction of $566,602.90. Following the transaction, the chief marketing officer owned 60,885 shares of the company’s stock, valued at $1,104,453.90. This trade represents a 33.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 97,890 shares of company stock worth $1,968,413. Company insiders own 4.80% of the company’s stock.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.